Global HIV Diagnostics Market By Product (Antibody Tests, Viral Identification Assays, CD4 Testing, Viral Load Testing, Early Infant Diagnosis) Is Expected To Reach USD 4.48 Billion In 2022: Grand View Research, Inc.
Global HIV Diagnostics Market is expected to reach USD 4.48 billion by 2022, growing at an estimated CAGR of 9.5% from 2015 to 2022, according to a new study by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities. View summary of this report @ http://www.grandviewresearch.com/industry-analysis/hivdiagnostics-market
Global HIV diagnostics market, By product, 2012-2022 (USD Million)
Table of Content Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumption 1.3. List of Data Sources Chapter 2. Executive Summary 2.1. HIV Diagnostics - Industry Snapshot and Key Buying Criteria, 2014 Chapter 3. HIV Diagnostics Industry Outlook 3.1. Market Segmentation 3.2. Market size and growth prospects 3.3. HIV Diagnostics Market dynamics 3.3.1. Market Driver Analysis 3.3.1.1. Growing prevalence of HIV 3.3.1.2. Introduction of rapid and portable diagnostic tests 3.3.1.3. Implementation of favorable government initiatives 3.3.2. Market Restraint Analysis 3.3.2.1. Low market penetration in emerging and underdeveloped economies 3.4. Industry Analysis - Porter’s 3.5. Key opportunities prioritized
3.6. HIV Diagnostics market - PESTEL analysis 3.7. HIV diagnostics unmet needs analysis 3.8. HIV diagnostics company market share analysis, 2014 Chapter 4. HIV Diagnostics Product Outlook 4.1. HIV Diagnostics Market Share By Product, 2014 & 2022 4.2. Antibody Tests 4.2.1. Antibody Tests Market Estimates and Forecasts, 2012 - 2022 (USD Million) 4.2.2. HIV-1 Screening Tests Market Estimates and Forecasts, 2012 - 2022 (USD Million) 4.2.2.1. ELISA/EIA 4.2.2.2. Home Access Dried Blood Spot 4.2.2.3. Rapid Tests 4.2.3. HIV-1 Confirmatory Tests Market Estimates and Forecasts, 2012 - 2022 (USD Million) 4.2.3.1. Western Blot Test 4.2.3.2. Indirect Immunoflourescent Antibody Assay (IFA) 4.2.3.3. Line ImmunoAssay (Cnf) 4.2.3.4. RadioImmuno-Precipitation (RIPA) 4.2.4. HIV-2 & Group O Diagnostic Tests Market Estimates and Forecasts, 2012 2022 (USD Million) 4.2.4.1. Blood Antibody Tests 4.2.4.2. DBS Tests 4.2.4.3. Line ImmunoAssay (HIV2) 4.3. Viral Identification Tests 4.3.1. Viral Identification Tests Market Estimates and Forecasts, 2012 - 2022 (USD Million) 4.3.1.1. p24 Antigen Test 4.3.1.2. Qualitative PCR Tests 4.3.1.3. Viral Culture 4.4. CD4 Testing 4.4.1. CD4 Testing Market Estimates and Forecasts, 2012 - 2022 (USD Million) 4.5. Viral Load testing 4.5.1. Viral load Testing Market Estimates and Forecasts, 2012 - 2022 (USD Million) 4.6. Early Infant Diagnostics 4.6.1. Early Infant Diagnostics Market Estimates and Forecasts, 2012 - 2022 (USD Million)
Chapter 5. HIV Diagnostics Regional Outlook 5.1. HIV Diagnostics Market Share By Region, 2014 & 2022 5.2. North America 5.2.1. Market Estimates and Forecasts, by Product, 2012 - 2022 (USD Million) 5.2.1.1. U.S. Market Estimates and Forecasts 5.2.1.2. Canada Market Estimates and Forecasts 5.3. Europe 5.3.1. Europe HIV Diagnostics Market Estimates and Forecasts, by Product, 2012 2022 (USD Million) 5.3.1.1. Germany Market Estimates and Forecasts 5.3.1.2. UK Market Estimates and Forecasts 5.4. Asia Pacific 5.4.1. Market Estimates and Forecasts, by Product, 2012 - 2022 (USD Million) 5.4.1.1. China Market Estimates and Forecasts 5.4.1.2. Japan Market Estimates and Forecasts 5.5. Latin America 5.5.1. Market Estimates and Forecasts, by Product, 2012 - 2022 (USD Million) 5.5.1.1. Brazil Market Estimates and Forecasts 5.6. MEA 5.6.1. MEA HIV Diagnostics Market Estimates and Forecasts, by Product, 2012 2022 (USD Million) 5.6.1.1. South Africa Market Estimates and Forecasts Chapter 6. Competitive Landscape 6.1. Alere Inc. 6.1.1. Company Overview 6.1.2. Financial Performance 6.1.3. Product Benchmarking 6.1.4. Strategic Initiative 6.2. Beckman Coulter 6.2.1. Company Overview 6.2.2. Financial Performance 6.2.3. Product Benchmarking 6.2.4. Strategic Initiative 6.3. BD Biosciences 6.3.1. Company Overview 6.3.2. Financial Performance 6.3.3. Product Benchmarking 6.3.4. Strategic Initiative
6.4. VIIV Healthcare 6.4.1. Company Overview 6.4.2. Financial Performance 6.4.3. Product Benchmarking 6.4.4. Strategic Initiative 6.5. Merch & Co. Inc. 6.5.1. Company Overview 6.5.2. Financial Performance 6.5.3. Product Benchmarking 6.5.4. Strategic Initiative 6.6. Gilead Sciences 6.6.1. Company Overview 6.6.2. Financial Performance 6.6.3. Product Benchmarking 6.6.4. Strategic Initiative 6.7. Janssen Therapeutics 6.7.1. Company Overview 6.7.2. Financial Performance 6.7.3. Product Benchmarking 6.7.4. Strategic Initiative 6.8. Bristol-Myers Squibb 6.8.1. Company Overview 6.8.2. Financial Performance 6.8.3. Product Benchmarking 6.8.4. Strategic Initiative 6.9. Abbvie Inc. 6.9.1. Company Overview 6.9.2. Financial Performance 6.9.3. Product Benchmarking 6.9.4. Strategic Initiative 6.10. Abbott Healthcare 6.10.1. Company Overview 6.10.2. Financial Performance 6.10.3. Product Benchmarking 6.10.4. Strategic Initiative 6.11. Partec 6.11.1. Company Overview 6.11.2. Financial Performance
6.11.3. Product Benchmarking 6.11.4. Strategic Initiative 6.12. Sysmex 6.12.1. Company Overview 6.12.2. Financial Performance 6.12.3. Product Benchmarking 6.12.4. Strategic Initiative 6.13. Apogee Flow Systems 6.13.1. Company Overview 6.13.2. Financial Performance 6.13.3. Product Benchmarking 6.13.4. Strategic Initiative 6.14. PointCare Technologies Inc. 6.14.1. Company Overview 6.14.2. Financial Performance 6.14.3. Product Benchmarking 6.14.4. Strategic Initiative 6.15. Zyomyx Inc. 6.15.1. Company Overview 6.15.2. Financial Performance 6.15.3. Product Benchmarking 6.15.4. Strategic Initiative 6.16. Mylan Inc. 6.16.1. Company Overview 6.16.2. Financial Performance 6.16.3. Product Benchmarking 6.16.4. Strategic Initiative 6.17. Roche Diagnostics 6.17.1. Company Overview 6.17.2. Financial Performance 6.17.3. Product Benchmarking 6.17.4. Strategic Initiative 6.18. Siemens Healthcare 6.18.1. Company Overview 6.18.2. Financial Performance 6.18.3. Product Benchmarking 6.18.4. Strategic Initiative 6.19. Siemens Healthcare
6.19.1. Company Overview 6.19.2. Financial Performance 6.19.3. Product Benchmarking 6.19.4. Strategic Initiative 6.20. Siemens Healthcare 6.20.1. Company Overview 6.20.2. Financial Performance 6.20.3. Product Benchmarking 6.20.4. Strategic Initiative
Browse full report diagnostics-market
@
http://www.grandviewresearch.com/industry-analysis/hiv-
List of Tables 1. HIV Diagnostics Market - Industry Summary & Key Buying Criteria, 2012 - 2022 2. HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 3. HIV Diagnostics - Key market driver analysis 4. HIV Diagnostics - Key market restraint analysis 5. North America HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 6. U.S. HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 7. Canada HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 8. Europe HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 9. Germany HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 10. UK HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 11. Asia Pacific HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 12. Japan HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 13. China HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 14. Latin America HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 15. Brazil HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 16. MEA HIV Diagnostics market, by product, 2012 - 2022 (USD Million) 17. South Africa HIV Diagnostics market, by product, 2012 - 2022 (USD Million)
For More Information visit http://www.grandviewresearch.com/industry-analysis/hivdiagnostics-market
List of Figures 1. HIV Diagnostics: Market segmentation 2. Global HIV Diagnostics market, (USD Million), 2012 - 2022 3. HIV Diagnostics: Market dynamics 4. HIV Diagnostics market - Porter’s Analysis 5. Key opportunities prioritized 2014 6. HIV Diagnostics market - PESTEL analysis 7. HIV Diagnostics: Company market share analysis, 2014 8. HIV Diagnostics market share, by product, 2014 & 2022 9. Global HLA testing market, 2012 - 2022 (USD Million) 10. Global antibody screening tests market, 2012 - 2022 (USD Million) 11. Global HIV-1 screening tests market, 2012 - 2022 (USD Million) 12. Global HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 13. Global HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 14. Global viral identification assays market, 2012 - 2022 (USD Million) 15. North America HIV Diagnostics market, 2012 - 2022 (USD Million) 16. North America HIV-1 screening tests market, 2012 - 2022 (USD Million) 17. North America HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 18. North America HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 19. North America viral identification assays market, 2012 - 2022 (USD Million) 20. U.S. HIV Diagnostics market, 2012 - 2022 (USD Million) 21. U.S. HIV-1 screening tests market, 2012 - 2022 (USD Million) 22. U.S. HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 23. U.S. HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 24. U.S. viral identification assays market, 2012 - 2022 (USD Million) 25. Canada HIV Diagnostics market, 2012 - 2022 (USD Million) 26. Canada HIV-1 screening tests market, 2012 - 2022 (USD Million) 27. Canada HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 28. Canada HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 29. Canada viral identification assays market, 2012 - 2022 (USD Million) 30. Europe HIV Diagnostics market, 2012 - 2022 (USD Million) 31. Europe HIV-1 screening tests market, 2012 - 2022 (USD Million) 32. Europe HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 33. Europe HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 34. Europe viral identification assays market, 2012 - 2022 (USD Million) 35. Germany HIV Diagnostics market, 2012 - 2022 (USD Million) 36. Germany HIV-1 screening tests market, 2012 - 2022 (USD Million) 37. Germany HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 38. Germany HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 39. Germany viral identification assays market, 2012 - 2022 (USD Million) 40. UK HIV Diagnostics market, 2012 - 2022 (USD Million) 41. UK HIV-1 screening tests market, 2012 - 2022 (USD Million) 42. UK HIV-1 confirmatory tests market, 2012 - 2022 (USD Million)
43. UK HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 44. UK viral identification assays market, 2012 - 2022 (USD Million) 45. Asia Pacific HIV Diagnostics market, 2012 - 2022 (USD Million) 46. Asia Pacific HIV-1 screening tests market, 2012 - 2022 (USD Million) 47. Asia Pacific HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 48. Asia Pacific HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 49. Asia Pacific viral identification assays market, 2012 - 2022 (USD Million) 50. Japan HIV Diagnostics market, 2012 - 2022 (USD Million) 51. Japan HIV-1 screening tests market, 2012 - 2022 (USD Million) 52. Japan HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 53. Japan HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 54. Japan viral identification assays market, 2012 - 2022 (USD Million) 55. China HIV Diagnostics market, 2012 - 2022 (USD Million) 56. China HIV-1 screening tests market, 2012 - 2022 (USD Million) 57. China HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 58. China HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 59. China viral identification assays market, 2012 - 2022 (USD Million) 60. Latin America HIV Diagnostics market, 2012 - 2022 (USD Million) 61. Latin America HIV-1 screening tests market, 2012 - 2022 (USD Million) 62. Latin America HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 63. Latin America HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 64. Latin America viral identification assays market, 2012 - 2022 (USD Million) 65. Brazil HIV Diagnostics market, 2012 - 2022 (USD Million) 66. Brazil HIV-1 screening tests market, 2012 - 2022 (USD Million) 67. Brazil HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 68. Brazil HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 69. Brazil viral identification assays market, 2012 - 2022 (USD Million) 70. MEA HIV Diagnostics market, 2012 - 2022 (USD Million) 71. MEA HIV-1 screening tests market, 2012 - 2022 (USD Million) 72. MEA HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 73. MEA HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 74. MEA viral identification assays market, 2012 - 2022 (USD Million) 75. South Africa HIV Diagnostics market, 2012 - 2022 (USD Million) 76. South Africa HIV-1 screening tests market, 2012 - 2022 (USD Million) 77. South Africa HIV-1 confirmatory tests market, 2012 - 2022 (USD Million) 78. South Africa HIV-2 & Group O diagnostic tests market, 2012 - 2022 (USD Million) 79. South Africa viral identification assays market, 2012 - 2022 (USD Million)
Further key findings from the study suggest:
Antibody HIV diagnostic tests accounted for the largest share of the market in 2014. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2. Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2014. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature and portable to the point of care to enhance their market usability and accessibility in resource limited HIV affected regions. It is expected that during the forecast period a number of novel point of care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products s expected to fuel the growth of this market over the forecast period. North America was observed to account for the largest share of the market in 2014, which can be attributed to the presence of a strong healthcare R&D scenario in which the presence of government funding and ongoing corporate efforts to enhance product portfolio are anticipated to accelerate the timelines for new product development. Furthermore, the presence of favorable reimbursements policies for HIV and other infectious diseases is also a factor accounting for this region’s large share. Asia Pacific is expected to grow at a relatively faster rate over the forecast period owing to, the presence of high levels of unmet market demand for HIV screening and testing. Moreover, collaborations among market participants from the western regions is another significant expected to boost the growth of Asia Pacific HIV diagnostics market during the forecast period. Key players of the market include Janssen Diagnostics, Daktari Diagnostics, Cepheid, Hologic and Chembio Diagnostic Systmes Inc.
Request free sample of this Report @ http://www.grandviewresearch.com/industryanalysis/hiv-diagnostics-market/request
For the purpose of this study, Grand View Research has segmented the HIV diagnostics market on the basis of product and region: HIV Diagnostics Product Outlook (Revenue, USD Million, 2012 – 2022)
Antibody Tests HIV-1 Screening Tests ELISA/EIA
Home Access Dried Blood Spot Rapid Tests (Dot plot, Agglutination Tests) HIV-1 Antibody Confirmatory Tests Western Blot Test Indirect Immunofluorescent Antibody Assay (IFA) Line Immunoassay RadioImmunoPrecipitation Assay (RIPA) HIV-2 & Group O Diagnostic Tests Blood Antibody Tests Dried Blood Spot (DBS) Test Others and (Oral, Urine) Viral Identification Assays P24 Antigen Test Qualitative PCR Tests Viral Culture CD4 Testing Viral Load Testing Early Infant Diagnostics
HIV Diagnostics Regional Outlook (Revenue, USD Million, 2012 – 2022)
North America U.S. U.S. HIV Diagnostics Market, by Product Canada Canada HIV Diagnostics Market, by Product Europe Germany Germany HIV Diagnostics Market, by Product UK UK HIV Diagnostics Market, by Product Asia Pacific Japan Japan HIV Diagnostics Market, by Product China China HIV Diagnostics Market, by Product Latin America Brazil Brazil HIV Diagnostics Market, by Product MEA South Africa South Africa HIV Diagnostics Market, by Product
Browse
All
Reports
of
this
category
@
http://www.grandviewresearch.com/industry/clinical-diagnostics
About Grand View Research Grand View Research, Inc. is a market research and consulting company that provides off-theshelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deepseated understanding of varied business environments, Grand View Research provides strategic objective insights.
Contact: Sherry James Corporate Sales Specialist, U.S.A. Grand View Research, Inc. United States Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com Website: Grand View Research Blog Site: http://www.divog.org/